by monexa-ai
Content generation failed - Recovery needed
Troubleshooting common website errors: practical solutions and tips.
Monexa for Analysts
Open the LLY command center with real-time data, filings, and AI analysis. Upgrade inside Monexa to trigger your 7-day Pro trial whenever you’re ready.
Failed after 3 attempts. Last error: Resource has been exhausted (e.g. check quota).
Eli Lilly’s FY2024 saw **net income more than double** and R&D surge, forcing a trade-off between reinvestment and near‑term cash conversion — a decisive signal for investors.
Eli Lilly delivered **$45.04B** revenue in FY2024 (+32.00%), powered by GLP‑1s and a guidance lift; strong margins mask compressed free cash flow after heavy capex.
Lilly’s GLP‑1 boom lifted revenue to **$45.04B** in 2024 and Q2 2025 GLP‑1 sales exceeded **$8.57B** — but heavy capex and working‑capital drag compress free cash flow.
LLY posted **FY2024 revenue of $45.04B (+32.00% YoY)** and **net income of $10.59B (+102.08% YoY)** while heavy capex compressed FCF to **$414M**. Orforglipron and retatrutide are the next execution tests.
Eli Lilly reported **$45.04B** revenue and **$10.59B** net income in FY2024 (+32.00% and +102.08% YoY) as tirzepatide momentum clashes with heavy capex and tight free cash flow.
FY2024 revenue rose to $45.04B (+32.01%) and net income doubled to $10.59B, but heavy capex and working-capital build compressed free cash flow to $0.41B and pushed net debt to $30.38B.